Drug Trial Radar · NCT06484192
Pain Control After Lumbar Spine Fusion
Last checked: Nov 20, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
428
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Rothman Institute OrthopaedicsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this randomized controlled trial is to determine if patients who receive non-steroidal anti-inflammatory medications (NSAIDs) following elective lumbar spinal fusion have increased rates of symptomatic nonunion requiring revision spinal surgery at two-years follow-up, compared to those who do not receive NSAIDs.
Conditions
- Spine Fusion
- NSAID (Non-Steroidal Anti-Inflammatory Drug)
- Postoperative Pain
Interventions
Naproxen 500 MgDrug
participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
KetorolacDrug
participants will receive Ketorolac (15 mg) immediately after surgery
OxyCODONE 5 mg Oral TabletDrug
participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
Metaxalone 800 MGDrug
participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fusion failureTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.